Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

被引：2
|
作者：
Zhao, Cathy Yunjia [1 ,2 ]
Chou, Shaun [1 ,3 ]
Liu, Rose Congwei [1 ,2 ]
Fernandez-Penas, Pablo [1 ,2 ]
机构：
[1] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[2] Univ Sydney, Med, Sydney, NSW, Australia
[3] Westmead Hosp, Inst Clin Pathol & Med Res, Sydney, NSW, Australia
来源：
PIGMENT CELL & MELANOMA RESEARCH | 2018年 / 31卷 / 02期
关键词：
MELANOCYTIC LESIONS;
D O I：
10.1111/pcmr.12669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Results of a study of horvermogens in patients with malignant melanoma before, during or after systemic therapy with checkpoint inhibitors or BRAF and MEK inhibitors
    Ehrmann, J.
    Wenzel, G. I.
    Vogt, T.
    Pfoehler, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 129 - 129
  • [32] Efficacy and safety of BRAF/MEK inhibitor rechallenge in patients with advanced melanoma: Systematic review and meta-analysis
    Priantti, Jonathan N.
    Vilbert, Maysa
    Madeira, Thiago
    Moraes, Francisco Cezar A.
    Hein, Erica C. Koch
    Cavalcante, Ludimila
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Genomic profiling of BRAFV600mutated metastatic melanoma patients initiating a BRAF inhibitor and MEK inhibitor combined therapy in routine care
    Louveau, B.
    Jouenne, F.
    De Moura, C. Reger
    Sadoux, A.
    Baroudjian, B.
    Delyon, J.
    Herms, F.
    De Masson, A.
    Da Meda, L.
    Battistella, M.
    Dumaz, N.
    Lebbe, C.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 131 - 132
  • [34] Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma
    Kazmierczak, Philipp M.
    Burton, Neal C.
    Keinrath, Georg
    Hirner-Eppeneder, Heidrun
    Schneider, Moritz J.
    Eschbach, Ralf S.
    Heimer, Maurice
    Solyanik, Olga
    Todica, Andrei
    Reiser, Maximilian F.
    Ricke, Jens
    Cyran, Clemens C.
    PLOS ONE, 2018, 13 (10):
  • [35] The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
    Chen, Peng
    Chen, Fucaho
    Zhou, Benhong
    CUTANEOUS AND OCULAR TOXICOLOGY, 2019, 38 (02) : 105 - 111
  • [36] Immunosuppressive Properties of MDSC and Neutrophils in Patients with Malignant Melanoma under Immune Checkpoint Inhibitor Therapy
    Petrova, V.
    Groth, C.
    Utikal, J.
    Umansky, V.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 28 - 28
  • [37] TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
    Thielmann, Carl M.
    Matull, Johanna
    Zaremba, Anne
    Murali, Rajmohan
    Chorti, Eleftheria
    Lodde, Georg
    Jansen, Philipp
    Herbst, Rudolf
    Terheyden, Patrick
    Utikal, Jochen
    Pfohler, Claudia
    Ulrich, Jens
    Kreuter, Alexander
    Mohr, Peter
    Gutzmer, Ralf
    Meier, Friedegund
    Dippel, Edgar
    Weichenthal, Michael
    Kretz, Julia
    Moeller, Inga
    Sucker, Antje
    Paschen, Annette
    Livingstone, Elisabeth
    Zimmer, Lisa
    Hadaschik, Eva
    Ugurel, Selma
    Schadendorf, Dirk
    Griewank, Klaus G.
    EUROPEAN JOURNAL OF CANCER, 2022, 161 : 99 - 107
  • [38] Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database
    Lindsay, Alistair C.
    Walker, Alexander M.
    Schneeweiss, Sebastian
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (01):
  • [39] Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis
    Yoshida, Kazuhiko
    Nagasaka, Naoki
    Kondo, Tsunenori
    Kobari, Yuki
    Ishihara, Hiroki
    Fukuda, Hironori
    Iizuka, Junpei
    Ishida, Hideki
    Takagi, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1538 - 1547
  • [40] First results of a clinical study investigating hearing and hearing impairment in melanoma patients under therapy with checkpointinhibitors or BRAF and MEK inhibitors
    Pfoehler, Claudia
    Ehrmann, Julia
    Saternus, Roman
    Wagner, Anne-Catherine
    Yordanova, Krista
    Adam, Leonie
    Schick, Bernhard
    Vogt, Thomas
    Wenzel, Gentiana I.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 237 - 237
12345